Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors

Clinical Chemistry

Volumn 42, Issue 9, 1996, Pages 1369-1381

  Pelkey, Timothy J ^a   Frierson Jr , Henry F ^a   Bruns, David E ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

carcinoma; immunology; melanoma; micrometastasis; mRNA; polymerase chain reaction; prostatic neoplasms; tumor markers; tyrosinase

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BONE MARROW; CANCER DIAGNOSIS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; METASTASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR;

EID: 0029738486     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.9.1369     Document Type: Review

References (163)

1. Salsbury AJ. The significance of the circulating cancer cell. Cancer Treat Rev 1975;2:55-72.
2. Hamdy FC, Lawry J, Anderson JB, Parsons MA, Rees RC, Williams JL. Circulating prostate-specific antigen positive cells correlate with metastatic prostate cancer. Br J Urol 1992;69:392-6.
3. Leather AJM, Gallegos NC, Kocjan G, Savage F, Smales CS, Hu W, et al. Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg 1993;80:777-80.
4. Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol 1990;8:736-40.
5. Osborne MP, Rosen PP. Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994;8:25-31.
6. Osborne MP, Wong GY, Gonzalez A, Potter C, Vlamis V, Cote RJ. Bone marrow micrometastases in breast cancer: the effect of systemic tumor cell burden on early relapse [Abstract 102]. Prog/Proc Am Soc Clin Oncol 1993;12:75.
7. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9: 1749-56.
8. Cote RJ, Rosen PP, Hakes TB, Sedira M, Bazxinet M, Kinne DW, et al. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early disease. Am J Surg Pathol 1988;12:333-40.
9. Mansi JL, Easton D, Berger U, Gazet JC, Ford HT, Dearnaley D, Coombes RC. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
10. Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC, Neville AM. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988;90:1-6.
11. Coombes RC, Berger U, Mansi J, Redding H, Poweles TJ, Neville AM, et al. Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer. Monogr Natl Cancer Inst 1986;1:51-3.
12. Redding WH, Coombes RC, Monaghan P, Clink HM, Imrie SF, Dearnaley DP, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;ii:1271-4.
13. Dearnaley DP, Ormerod MG, Sloane JP. Micrometastases in breast cancer: long-term follow-up of the first patient cohort. Eur J Cancer 1991;27:236-9.
14. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-9.
15. Harbeck N, Untch M, Eiermann W. Detection of tumor cells in the bone marrow at primary therapy: a new prognostic criterion in breast cancer? [Abstract] J Cancer Res Clin Oncol 1990; 116(Suppl I):49.
16. Wong GY, Osborne MP. Breast cancer bone marrow micrometastasis: a sensitive statistical analysis of the effect of systemic tumor cell burden on early relapse [Abstract]. Breast Cancer Res Treat 1992;19:171.
17. Salvadori B, Squicciarini P, Rovini D, Orefice S, Andreola S, Rilke F, et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer 1990;26:865-7.
18. Schlimok G, Funke I, Holzmann B, Göttlinger G, Schmidt G, Hauser H, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A 1987;84: 8672-6.
19. Neville AM. Breast cancer micrometastasis in lymph nodes and bone marrow are prognostically significant. Ann Oncol 1991;2: 13-4.
20. Ellis G, Ferguson M, Yamanaka E, Livingston RB, Gown AM. Monoclonal antibodies for detection of occult carcinoma cells on bone marrow of breast cancer patients. Cancer 1989;63:2509-14.
21. Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC, et al. Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 1987;295:1093-6.
22. Mansi JL, Berger U, McDonnell T, Pople A, Rayter Z, Gazet JC, Coombes RC. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989;7:445-9.
23. Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 1991;51:2706-9.
24. Osborne MP, Asina S, Wong GY, Old LJ, Cote RJ. Immunofluorescent monoclonal antibody detection of breast cancer in bone marrow: sensitivity in a model system. Cancer Res 1989;49: 2510-3.
25. Porro G, Menard S, Tabliabue E, Orefice S, Salvadori B, Squicciarini P, et al. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer 1988;61:2407-11.
26. 7. Proc Natl Acad Sci U S A 1995;92:537-41.
27. Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol 1990;94:8-13.
28. Clevenger CV, Khandewal M, Stadtmauer E, Jardines L. Detection of bone marrow breast carcinoma metastasis using multiparameter flow cytometry. Ann NY Acad Sci 1993;677:400-1.
29. Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993;53: 1027-31.
30. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, Riethmuller G. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996;347: 649-53.
31. Leonard RCF, Duncan LS, Hay FG. Immunocytological detection of residual marrow disease at clinical remission predicts metastatic relapse in small cell lung cancer. Cancer Res 1990;50:6545-8.
32. Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, Riethmuller G. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991;27:1461-5.
33. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-9.
34. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-24.
35. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991;51:4712-5.
36. Bretton PR, Melamed MR, Fair WR, Cote RJ. Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate 1994;25:108-14.
37. Mansi JL, Berger U, Wilson P, Shearer R, Coombes RC. Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques. J Urol 1988;139:545-8.
38. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammon GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324: 219-26.
39. Moul JW, Lewis DJ, Ross AA, Kahn DG, Ho CK, McLeod DG. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. Urology 1994;43:68-73.
40. Bettelheim R, Price KN, Gelber RD, Davis BW, Castiglione M, Goldhirsch A, et al. International Ludwig Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990;335:1565-8.
41. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992;66:523-7.
42. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
43. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
44. Trojani M, de Mascarel I, Coindre JM, Bonichon F. Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;56:838-9.
45. Munro-Neville A. Are breast cancer axillary node micrometastases worth detecting? J Pathol 1990;161:283-4.
46. Wilkinson EJ, Hause LL, Hoffman RG, Kuzma JF, Rothwell DJ, Donegan WL, et al. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol Annu 1982;17:67-91.
47. Galea MH, Athanassiou E, Robertson JFR, Bell J, Ellis IO, Elston CW, Blamey RW. Axillary micrometastases from breast carcinoma: immunohistochemical detection with NCRC-11 and CAM5.2 [Abstract]. Br J Cancer 1990;62(Suppl XII):019.
48. Byrne J, Waldron R, McAvinchey D, Dervan P. The use of monoclonal antibodies for the histopathological detection of mammary axillary micrometastases. Eur J Surg Oncol 1987;13:409-11.
49. Bussolati G, Gugliotta P, Morra I, Pietribiasi F, Berardengo E. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma of the breast. Br J Cancer 1986;54: 631-6.
50. Sedmak DD, Meineke TA, Knechtges DS, Anderson J. Prognostic significance of cytokeratin-positive breast cancer metastases. Mod Pathol 1989;2:516-20.
51. Byrne J, Horgan PH, England S, Callaghan J, Given HF. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometases in axilllary lymph nodes draining primary breast carcinoma. Eur J Cancer 1992;28: 658-60.
52. Passlick B, Izbicki JR, Kubushchok B, Nathrath W, Thetter O, Pichlmeier U, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994;12:1827-32.
53. Chen A, Perez S, Holmes EC, Wang H, Coulson WF, Went DR, Cochran AJ. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 85:493-8.
54. Cutait R, Alves VAF, Lopes LC, Cutait DE, Borges JLA, Singer J, et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991;34:917-20.
55. Gunven P, Maruyama K, Okabayashi K, Sasako M, Kinoshita T. Non-ominous micrometastases of gastric cancer. Br J Surg 1991; 78:352-4.
56. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole K, et al. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-8.
57. Ghossein R, Scher H, Gerald W, Kelly WK, Curley T, Amsterdam A, et al. Detection of circulating tumor cells in peripheral blood of patients with advanced prostatic carcinoma [Abstract]. Proc Am Soc Clin Oncol 1994;13:735A.
58. Ghossein R, Scher H, Gerald W, Hoffman A, Kelly W, Curley T, et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995;13:1195-200.
59. Israeli RS, Miller WH, Su SL, Powell CT, Fair WR, Samadi DS, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994;54:6306-10.
60. Israeli RS, Miller WH, Su SL, Samadi DS, Powell CT, Heston WDW, et al. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 1995;153:573-7.
61. Loric S, Dumas F, Eschwege P, Blanchet P, Benoit G, Jardin A, Lacour B. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 1995; 41:1698-704.
62. Su SL, Huang IP, Fair WR, Powell CT, Heston WDW. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441-3.
63. Jaakkola S, Vornanen T, Leionen J, Rannikko S, Stenman UH. Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. Clin Chem 1995;41:182-6.
64. Katz AE, Seaman E, Olsson CA, O'Toole KM, Raffo AJ, McMahon D, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994;43: 765-75.
65. Katz AE, deVries GM, Begg MD, Raffo AJ, Cama C, O'Toole K, et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995;75:1642-8.
66. Kunimi K, Kobayashi T, Imao T, Endo Y, Uchibayashi T, Sasaki T, Ohkawa M. Molecular staging of hematogenous microdissemination in prostate cancer [Abstract 463A]. J Urol 1995;153(Suppl): 938.
67. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992;53:6110-2.
68. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, et al. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994;12:2634-9.
69. Arfman EW, Vessella RL, Stray JE, Lange PH, Su SL, Fair WR, Heston WDW. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of circulating prostate cancer cells - a methodological and early clinical trial evaluation with primers for PSA and PSM [Abstract 261]. J Urol 1995;153:294A.
70. Sokoloff M, Tso CL, Kaboo R, Franklin J, deKernion J, Pang S, Belldegrun A. Super-sensitive and quantitative polymerase chain reaction (PCR): an innovative technique for staging and monitoring prostate cancer [Abstract 262]. J Urol 1995;153:294A.
71. Oefelein MG, Kaul K, Herz B, Blum MD, Holland JM, Keeler TC, et al. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol 1996;155:238-42.
72. Vessella R, Stray J, Arfman E, Ellis W, Lange P. Reverse transcription polymerase chain reaction (RT-PCR) detects metastatic prostate cancer cells in lymph nodes, blood and potentially in bone marrow using PSA-mRNA as template [Abstract 740]. J Urol 1994;151:412A.
73. Vessella RL, Blouke KA, Stray JE, Riley DE, Spies AG, Arfman EW, Lange PH [Abstract 2367]. Proc Am Assoc Cancer Res 1992;33: 396.
74. deVries G, Olsson CA, Raffo A, Cama C, O'Toole K, Benson M, et al. The molecular staging of prostate cancer using an RT-PCR assay: a study of 100 radical prostatectomy patients [Abstract 263]. J Urol 1995;153:.
75. Wood DP, Banks ER, Humphreys S, Rangnekar VM. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 1994;42:505-11.
76. Wood DP, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994;74:2533-40.
77. Eschwege P, Dumas F, Blanchet P, LeMaire V, Benoit G, Jardin A, et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995;346:1528-30.
78. Galvan B, Christopoulos TK, Diamandis EP. Detection of prostate-specific antigen mRNA by reverse transcription polymerase chain reaction and time-resolved fluorometry. Clin Chem 1995;41: 1705-9.
79. de Vere White RW, Meyers F, Larken E, Soares S, Gumerlock P, Chi SG. Bone marrow molecular staging of prostatic carcinoma: does it help? [Abstract 937]. J Urol 1995;153(Suppl)937:463A.
80. Heston WDW. Detection of hematogenous dissemination of prostatic cancer by RT-PCR with primers specific for prostate-specific membrane antigen [Editorial]. Clin Chem 1995;41:1687-8.
81. Deguchi T, Doi T, Ehara H, Ito S, Takahashi Y, Nishino Y, et al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer 1994;74:1595-600.
82. Wu A, Ben-Ezra J, Colomber A. Detection of micrometastasis in breast cancer by the polymerase chain reaction: a feasibility study [Abstract 641]. Lab Invest 1990;62:109A.
83. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994;12:725-9.
84. Fields KK, Moscinski LC, Hebel DC, Perkins JB, Elfenbein GJ. Polymerase chain reaction (PCR) evaluation of bone marrow micrometastases in metastatic breast cancer [Abstract 54]. Breast Cancer Res Treat 1993;27:144.
85. Hoon DSB, Doi F, Fiuliano AE, Schmid P, Conrad AJ. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction [Letter]. Cancer 1995;76:533-5.
86. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994;12:475-82.
87. Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55: 3417-20.
88. Noguchi S, Aihara T, Nakamori S, Motomura K, Inaji H, Imaoka S, Koyama H. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Cancer 1994;74:1595-600.
89. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 1996;148:649-56.
90. Schoenfeld A, Luqmani Y, Smith D, O'Reilly S, Shousha S, Sinnett HD, Coombes RC. Detection of breast cancer micrometases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994;54:2986-90.
91. Komeda T, Fukuda Y, Sando T, Kita R, Furukawa M, Nishida N, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral blood. Cancer 1995;75:2214-9.
92. Matsumura M, Niwa Y, Kato N, Komatsu Y, Shiina S, Kawabe T, et al. Detection of alpha-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology 1994;20:1418-25.
93. Hillaire S, Barbu V, Boucher E, Moukhtar M, Poupon R. Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology 1994;106:239-42.
94. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 1995;71:278-81.
95. Hayashi N, Arakawa H, Nagase H, Yanagisawa A, Kato Y, Ohta H, et al. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res 1994;54:3853-6.
96. Betz C, Papadopoulos T, Buchwald J, Dammrich J, Muller-Hermelink HK. Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small-cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55: 4283-6.
97. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991;338:1227-9.
98. Tobal K, Sherman LS, Foss AJE, Lightman SL. Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest Ophthalmol Vis Sci 1993;34: 2622-5.
99. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 1993;101: 887-9.
100. Hoon DSB, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-16.
101. Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 1995;72:155-9.
102. Brossart P, Keilholz U, Scheibenbogen C, Mohler T, Willhauck M, Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother 1994;15:38-41.
103. Wang X, Heller R, Van Voorhis N, Cruse CW, Glass F, Fenske N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
104. Mattano LA, Moss TH, Eerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 1992;52:4701-5.
105. Naito H, Kuzumaki N, Uchino J, Kobayashi R, Shikano T, Ishikawa Y, Matsumoto S. Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction. Eur J Cancer 1991;27:762-5.
106. Miyajima Y, Kato K, Numata S, Kudo K, Horibe K. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1995;75:2757-61.
107. Burchill SA, Bradbury FM, Smith B, Lewis IJ, Selby P. Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer 1994;57:671-5.
108. Miyamura K, Tanimoto M, Morishima Y, Horibe K, Yamamoto K, Akatsuka M. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992;79:1366-70.
109. Takatsuki H, Umemura T, Sadamura S, Yamashita S, Goto T, Abe Y, et al. Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RAR alpha fusion mRNA: a study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation. Leukemia 1995;9:889-92.
110. Nollau P, Jung R, Neumaier M, Wagener C. Tumour diagnosis by PCR-based detection of tumour cells. Scand J Clin Lab Invest (Suppl) 1995;221:116-21.
111. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
112. Trumper LH, Burger B, von Bonin F, Hintze A, von Blohn G, Pfreundschuh M. Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. Br J Cancer 1994;70:278-84.
113. Boyle JO, Mao L, Brennan JA, Koch WM, Eisele DW, Saunders JR, Sidransky D. Gene mutations in saliva as molecular markers for head and neck squamous cells carcinomas. Am J Surg 1994; 168:429-32.
114. van Es JM, Polak MM, van den Berg FM, Ramsoekh TB, Craanen ME, Hruban RH, Offerhaus GJ. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol 1995;48:218-22.
115. Fidler IJ, Gersten DM, Hart IR. The biology of cancer invasion and metastasis. Adv Cancer Res 1978;28:150-250.
116. Weiss L. Metastatic inefficiency: causes and consequences. Cancer Rev 1986;3:1-24.
117. Glaves D, Huben RP, Weiss L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer 1988;57: 32-5.
118. Tarin D, Price JE, Kettlewell MGW, Souter RG, Vass ACR, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritovenous shunts. Cancer Res 1984;44:3584-92.
119. Fidler IJ. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur J Cancer 1973;9:223-7.
120. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
121. Koike A. Mechanism of blood-borne metastases. I. Some factors affecting lodgement and growth of tumor cells in the lungs. Cancer 1964;17:450-60.
122. Mayhew E, Glaves D. Quantitation of tumorigenic disseminating and arrested cancer cells. Br J Cancer 1984;50:159-66.
123. Glaves D. Correlation between circulating cancer cells and incidence of metastases. Br J Cancer 1983;48:665-73.
124. Fidler IJ. Selection of successive tumour lines for metastasis. Nature New Biol 1973;242:148-9.
125. Weiss L, Mayhew E, Glaves D, Holmes JC. Metastatic inefficiency in mice bearing B16 melanomas. Br J Cancer 1982;45: 44-53.
126. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975;35: 512-6.
127. Liotta LA, Kleinerman J, Saidel GM. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976;36:889-94.
128. Rinker-Schaeffer CS, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 1994;25:249-65.
129. Miettinen M. Keratin immunohistochemistry: update of applications and pitfalls. Pathol Annu 1991;113-43.
130. Thomas P, Battifora H. Keratins versus epithelial membrane antigen in tumor diagnosis - an immunohistochemical comparison of five monoclonal antibodies. Hum Pathol 1987;18:728-34.
131. Rabkin MS, Kjeldsberg CR. Epithelial membrane antigen staining patterns of histiocytic lesions. Arch Pathol Lab Med 1987;111: 337-8.
132. Pinkus GS, Kurtin PJ. Epithelial membrane antigen - a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies. Hum Pathol 1985; 16:929-40.
133. Smith M, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995;55:2640-4.
134. Henke W, Jung M, Jung K, Lein M, Schlechte H, Berndt C, et al. Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells [Letter]. Clin Chem 1996;42: 1499-500.
135. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54:1807-11.
136. Trover JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-8.
137. Wright GL, Haley C, Beckett ML Schellhammer PF. Expression of prostate-specific antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
138. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, et al. Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer 1995;72:583-8.
139. Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of the prostate biomarker 7E11-C5 in primary and metastatic prostate carcinoma [Abstract 1392]. Clin Invest 1994;35:233.
140. Henttu P, Liao S, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 1992;130:766-72.
141. Diamandis EP, Yu H. Prostate cancer, prostate-specific antigen, and the polymerase chain reaction [Editorial]. Clin Chem 1995; 41:177-9.
142. Yu H, Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 1993;39:2108-13.
143. Check WA. Amplification assays: now it's a horserace. CAP Today 1995;9:1.
144. Grassi G, Zentilin L, Tafuro S, Diviacco S, Ventura A, Falaschi A, Giacca M. A rapid procedure for the quantitation of low abundance RNAs by competitive reverse transcription-polymerase chain reaction. Nucleic Acids Res 1994;22:4547-9.
145. Karet FE, Charnock-Jones CS, Harrison-Woolrych ML, O'Reilly G, Davenport AP, Smith SK. Quantification of mRNA in human tissue using fluorescent nested reverse-transcriptase polymerase chain reaction. Anal Biochem 1994;220:384-90.
146. Pane F, Salera A, Mostarda H, Salvatore F, Sacchetti L. Estimation of extremely low amounts of single mRNAs by quantitative noncompetitive reverse transcription-polymerase chain reaction assay in biological specimens from normal and neoplastic cells. Anal Biochem 1995;225:362-6.
147. Debruyne FM, Collins VP, van Dekken H, Jenkins RB, Klocker H, Schalken JA, et al. Cytogenetics of prostate cancer. Consensus conference on diagnosis and prognostic parameters in localized prostate cancer. Scand J Urol Nephrol Suppl 1994;162:65-71.
148. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-9.
149. Effert PJ, McCoy RH, Walther PJ, Liu ET. p53 gene alterations in human prostate carcinoma. J Urol 1993;150:257-61.
150. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;12:884-6.
151. Colombel M, Symmons F, Gil S, O'Toole K, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
152. Myers RB, Srivastava S, Grizzle WE. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J Urol 1995;153:1572-4.
153. Sharpe JC, Abel PD, Gilbertson JA, Brawn P, Foster CS. Modulated expression of human leukocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol 1994;74:609-14.
154. Liu AY. Expression of CD44 in prostate cancer cells. Cancer Lett 1994;76:63-9.
155. Spires SE, Banks ER, Davey DD, Jennings CD, Wood DP Jr, Cibull ML. Proliferating cell nuclear antigen in prostatic adenocarcinoma: correlation with established prognostic indicators. Urology 1994;43:660-6.
156. Harper ME, Goddard L, Wilson DW, Matanhelia SS, Conn IG, Peeling WB, Griffiths K. Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 1992;21:75-84.
157. Lipford GB, Wright GL. Comparative study of monoclonal antibodies TURP-27 and HNK-1: their relationship to neural cell adhesion molecules and prostate tumor-associated antigens. Cancer Res 1991;51:2296-301.
158. Wright GL, Beckett ML, Lipford GB, Haley CL, Schellhammer PF. A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27. Int J Cancer 1991;47:717-25.
159. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 1994;54:6344-7.
160. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78:1536-9.
161. Wilke WW, Sutton LD, Jones RN. Automation of polymerase chain reaction tests to achieve acceptable contamination rates [Tech Brief]. Clin Chem 1995;41:622-3.
162. Rys PN, Persing DH. Preventing false positives: quantitative evaluation of three protocols for inactivation of polymerase chain reaction amplification products. J Clin Microbiol 1993;31: 2356-60.
163. NCCLS. Proposed Guideline NRSCL8-P2. Nomenclature and definitions for use in the NRSCL and other NCCLS documents, 2nd ed. Villanova, PA: National Committee for Clinical Laboratory Standards, February 1993.